TransMedics Group, Inc. $TMDX Shares Bought by Biondo Investment Advisors LLC

Key Points

• Biondo Investment Advisors LLC increased its stake in TransMedics Group by 8.6%, owning 58,070 shares after acquiring an additional 4,620 shares, valued at approximately $3.9 million.
• Several research firms have raised their price targets for TransMedics Group, with Oppenheimer increasing it to $150.00 and Morgan Stanley to $123.00, highlighting strong institutional interest in the stock.
• TransMedics Group reported a significant 37.7% year-over-year revenue increase in its recent earnings, with earnings per share of $0.92 exceeding analyst expectations.

Biondo Investment Advisors LLC grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 8.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 58,070 shares of the company's stock after acquiring an additional 4,620 shares during the quarter. Biondo Investment Advisors LLC owned about 0.17% of TransMedics Group worth $3,907,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. NBC Securities Inc. acquired a new stake in TransMedics Group during the first quarter worth approximately $25,000. Hager Investment Management Services LLC boosted its holdings in shares of TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after buying an additional 205 shares in the last quarter. CWM LLC grew its position in shares of TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after buying an additional 155 shares during the last quarter. AlphaQuest LLC raised its stake in TransMedics Group by 55.6% during the 1st quarter. AlphaQuest LLC now owns 1,288 shares of the company's stock worth $87,000 after acquiring an additional 460 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock worth $105,000 after acquiring an additional 1,324 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday. Canaccord Genuity Group upped their target price on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and an average price target of $123.00.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Stock Performance

TMDX stock traded up $0.08 during trading on Thursday, hitting $117.46. The company had a trading volume of 274,009 shares, compared to its average volume of 1,313,283. The firm has a 50-day moving average price of $120.56 and a 200-day moving average price of $102.19. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The firm has a market cap of $4.00 billion, a PE ratio of 60.86 and a beta of 2.09. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $172.78.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. During the same period last year, the business posted $0.35 EPS. The company's revenue was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.